[go: up one dir, main page]

PE20151726A1 - Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles - Google Patents

Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles

Info

Publication number
PE20151726A1
PE20151726A1 PE2015002122A PE2015002122A PE20151726A1 PE 20151726 A1 PE20151726 A1 PE 20151726A1 PE 2015002122 A PE2015002122 A PE 2015002122A PE 2015002122 A PE2015002122 A PE 2015002122A PE 20151726 A1 PE20151726 A1 PE 20151726A1
Authority
PE
Peru
Prior art keywords
imidazothiazoles
combination
macrocyclic lactones
veterinary formulations
stable veterinary
Prior art date
Application number
PE2015002122A
Other languages
English (en)
Inventor
Rose Guy Francis De
Sachin Pundlik Kolhe
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50694063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151726(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PE20151726A1 publication Critical patent/PE20151726A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017Non-human animal skin, e.g. pour-on, spot-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Referida a una composicion para el tratamiento de infecciones parasitarias en animales, que comprende: una lactona macrociclica tal como doramectina o moxidectina en una cantidad de entre 0,1% p/p a 1% p/p, de 4,0% p/p a 24% p/p de levamisol, un potenciador de estabilidad de aminoazucar tal como glucosamina o meglumina en una cantidad de entre 0,01% p/p a 0,2% p/p, un vehiculo farmaceutica o veterinariamente aceptable y al menos un agente antiparasitario adicional tal como benzimidazol
PE2015002122A 2013-04-12 2014-04-10 Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles PE20151726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361811138P 2013-04-12 2013-04-12

Publications (1)

Publication Number Publication Date
PE20151726A1 true PE20151726A1 (es) 2015-11-18

Family

ID=50694063

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002122A PE20151726A1 (es) 2013-04-12 2014-04-10 Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles

Country Status (11)

Country Link
US (1) US10307405B2 (es)
EP (1) EP2983712B1 (es)
BR (1) BR112015025875B1 (es)
CL (1) CL2015002976A1 (es)
CR (1) CR20150508A (es)
ES (1) ES2846820T3 (es)
MX (1) MX364170B (es)
NZ (1) NZ712345A (es)
PE (1) PE20151726A1 (es)
PL (1) PL2983712T3 (es)
WO (1) WO2014169092A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102017010598A2 (pt) * 2017-05-19 2018-12-04 Flavio Alves Da Rocha composições veterinárias de liberação retardada para controle de ovos e larvas de helmintos nas fezes dos ruminantes, uso das composições, uso de antelmínticos com essa finalidade
EP3713413A1 (en) 2017-11-23 2020-09-30 Ceva Sante Animale Composition for treating parasites infestations
DK3846786T3 (da) * 2018-09-05 2024-12-02 Zoetis Services Llc Velsmagende antiparasitære formuleringer
SI3815677T1 (sl) 2019-10-30 2023-12-29 Krka, D.D., Novo Mesto Stabilni veterinarski sestavek, ki obsega moksidektin in imidakloprid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4144352A (en) 1977-12-19 1979-03-13 Merck & Co., Inc. Milbemycin compounds as anthelmintic agents
EP0165900A3 (de) 1984-06-08 1986-05-28 Ciba-Geigy Ag Neue Lactone, Verfahren zu ihrer Herstellung und ihre Verwendung in der Schädlingsbekämpfung
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
DK1276748T3 (da) 2000-04-27 2006-03-20 Sankyo Lifetech Company Ltd 13-substituerede milbemycinderivater, deres fremstilling og deres anvendelse over for insekter og andre skadedyr
US7348417B2 (en) 2003-08-07 2008-03-25 Wyeth Method of purifying moxidectin through crystallization
US7671034B2 (en) * 2003-12-19 2010-03-02 Merial Limited Stabilized formulation of ivermectin feed premix with an extended shelf life
WO2006006021A2 (en) * 2004-06-28 2006-01-19 Glenmark Pharmaceuticals Limited Stabilized pharmaceutical compositions of preferably a statin
WO2006069580A1 (en) * 2004-12-30 2006-07-06 Cheminova A/S Oil-in-water formulation of avermectins
US7840123B2 (en) * 2007-06-21 2010-11-23 S.C. Johnson & Son, Inc. Diffusion device
BRPI0819849B8 (pt) 2007-11-26 2021-05-25 Merial Ltd sistemas de solvente para formulações pour on para combater parasitas
AU2009283313C1 (en) * 2008-08-18 2014-07-31 Intervet Ineternational B.V. Anthelmintic compositions
UA108641C2 (uk) * 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
WO2011143479A1 (en) 2010-05-12 2011-11-17 Merial Limited Injectable parasiticidal formulations of levamisole and macrocyclic lactones
PL3351546T3 (pl) * 2011-12-02 2024-09-09 Boehringer Ingelheim Vetmedica Gmbh Długodziałające wstrzykiwalne postaci moksydektyny

Also Published As

Publication number Publication date
CL2015002976A1 (es) 2016-05-06
BR112015025875A2 (pt) 2017-07-25
WO2014169092A1 (en) 2014-10-16
MX2015014310A (es) 2016-02-16
ES2846820T3 (es) 2021-07-29
US20160051524A1 (en) 2016-02-25
BR112015025875B1 (pt) 2021-06-29
EP2983712A1 (en) 2016-02-17
NZ712345A (en) 2016-04-29
EP2983712B1 (en) 2020-11-25
MX364170B (es) 2019-04-15
CR20150508A (es) 2015-11-18
PL2983712T3 (pl) 2021-05-31
US10307405B2 (en) 2019-06-04

Similar Documents

Publication Publication Date Title
CL2012002764A1 (es) Composicion veterinaria liquida que comprende fipronil, praziquantel, un agente activo regulador del crecimiento, amervectina o milbemicina, un vehiculo, y opcionalmente un inhibidor de la cristalizacion; y su uso para el tratamiento o prevencion de una infecion o infestacion parasitaria.
NI201400842A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas.
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
CL2014000601A1 (es) Composición tópica veterinaria que comprende al menos un agente activo derivado de isoxazolina; y uso de la composición para el tratamiento o prevención de una infestación o infección por parásitos en un animal.
CR20120623A (es) Composiciones Farmacéuticas que comprenden Monohidrato de Lactato de 4-amino-5-Fluoro-3-[6-(4-Metil-Piperazin-1-Il)-1H- Bencimidazol-2-Il]-1H-Quinolin-2-Ona
NI201500118A (es) Imidazopiridazinas sustituidas
SV2013004451A (es) Compuestos y su uso
DOP2016000007A (es) Pirazolpiridinas sustituidas
NI201700078A (es) Pirazolpiridinaminas
CO2017011284A2 (es) Combinaciones antihelmínticas y métodos de uso de ellas
PE20151726A1 (es) Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles
AR099829A1 (es) Formulaciones veterinarias antihelmínticas estables
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
CL2008001536A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente antimicrobiano como ciprofloxacino y un agente antioxidante como acido ascorbico, la concentracion de ciprofloxacino va desde 250 mg hasta 1 gr y desde 50 mg hasta 200 mg para acido ascorbico, en una unidad de dosis; y uso en infecciones urinarias.
NZ594610A (en) Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants
TR201203087A2 (tr) Seftibüten ve klavulanik asit formülasyonları.
TR201203084A2 (tr) Sefditoren pivoksil ve klavulanik asit içeren formülasyonlar.
TR201203083A2 (tr) Sefdinir ve klavulanik asit içeren farmasötik dozaj formu.

Legal Events

Date Code Title Description
FD Application declared void or lapsed